PCSK9 inhibitors might finally reach their clinical potential in the patients who need them most, after the ELL-ASCVD study demonstrated that a Meds-to-Beds program delivering these medications before hospital discharge significantly improved patient uptake.
- PCSK9is are guideline-recommended for ASCVD patients but face significant access barriers including physician inertia, insurance denials (31% rejection rate), and complex prior authorization processes despite 60% price reductions.
- High-risk post-revascularization patients are an ideal population for aggressive LDL lowering, yet many fail to achieve target LDL levels due to these barriers.
The ELL-ASCVD program enrolled 72 patients immediately following their revascularization procedures, with 69% post-PCI, 18% post-CABG, and 13% post-peripheral interventions, finding that the Meds-to-Beds approach led to significant improvement in patient outcomes.
- LDL goal achievement (< 70 mg/dL) reached 92% at 6 months with the M2B program versus 40% in historical controls.
- Better yet, 79% of patients achieved the < 55 mg/dL target versus 25% with standard care.
- Median LDL reduction was 66% with PCSK9is versus 25% in controls.
- The program successfully navigated insurance coverage for most patients despite a diverse payor mix (33% Medicare, 36% Medicaid, and 21% private insurance).
Even with demonstrated clinical benefits and price reductions, physician inertia could continue to prevent appropriate PCSK9i adoption. Real-world implementation challenges included…
- Twelve patients whose prescriptions were withdrawn by outpatient providers, reflecting “disagreement with GDMT or preference for alternative approaches.”
- Eight patients who couldn’t obtain insurance approval.
- Four patients who faced prohibitive out-of-pocket costs, illustrating persistent barriers despite manufacturer price cuts.
The Takeaway
The ELL-ASCVD study demonstrates that access barriers, not medication efficacy, represent the primary obstacle to optimal PCSK9 inhibitor use in high-risk patients. Whatever those barriers may be, it’s important to remember that they can be removed with the right effort.
